Motor Neurone Disease Trial, Recruiting NCT03174938 Sponsor: Skane University Hospital Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT03174938
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has five separate groups (called cohorts). People may be considered for one of the following groups:

Group A – Cognitively healthy, aged 40–65:

  • People aged between 40 and 65 years old
  • People who a specialist doctor has assessed as having no signs of cognitive (thinking or memory) symptoms
  • People who score between 27 and 30 on a standard memory and thinking test (called the MMSE) at the screening visit
  • People who do not meet the medical criteria for mild cognitive impairment (MCI) or any form of dementia, as defined by a standard diagnostic guideline (DSM-5)
  • People who speak and understand Swedish well enough to fully understand the study information and complete the thinking tests without needing an interpreter

Group B – Cognitively healthy, aged 66–100:

  • People aged between 66 and 100 years old
  • People who a specialist doctor has assessed as having no signs of cognitive symptoms
  • People who score between 26 and 30 on the MMSE at the screening visit
  • People who do not meet the medical criteria for MCI or any form of dementia (DSM-5)
  • People who speak and understand Swedish well enough to fully understand the study information and complete the thinking tests without needing an interpreter

Group C – Subjective cognitive decline or mild cognitive impairment:

  • People aged between 40 and 100 years old
  • People who have been referred to a memory clinic because of thinking or memory concerns noticed by themselves or someone close to them — these concerns may relate to memory, planning, language, spatial awareness, movement, or social understanding
  • People who score between 24 and 30 on the MMSE at the screening visit
  • People who do not meet the full medical criteria for dementia (DSM-5)
  • People whose treating doctor, after a full clinical review including brain scans and fluid tests, believes the symptoms are likely caused by an early brain condition — this includes people with certain abnormal test results in their spinal fluid that are linked to early Alzheimer's-related brain changes, or people with mild cognitive impairment linked to Parkinson's disease, Lewy body disease, vascular brain disease, or frontotemporal dementia (confirm with trial site)
  • People who speak and understand Swedish well enough to fully understand the study information and complete the thinking tests without needing an interpreter

Group D – Dementia due to Alzheimer's disease:

  • People aged between 40 and 100 years old
  • People who have been referred to a memory clinic because of thinking or memory concerns noticed by themselves or someone close to them — these concerns may relate to memory, planning, language, spatial awareness, or movement
  • People who score between 12 and 26 on the MMSE at the screening visit
  • People who meet the medical criteria for dementia due to Alzheimer's disease (DSM-5)
  • People who speak and understand Swedish well enough to fully understand the study information and complete the thinking tests without needing an interpreter

Group E – Other types of dementia or related conditions:

  • People aged between 40 and 100 years old
  • People who meet the medical criteria for dementia or a related neurological condition, specifically: frontotemporal dementia, Parkinson's disease dementia, Lewy body dementia, subcortical vascular dementia, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, or ALS (confirm specific diagnostic criteria with trial site)
  • People who speak and understand Swedish well enough to fully understand the study information and complete the thinking tests without needing an interpreter

Who may not be able to join (applies to all groups):

  • People with a serious, unstable physical illness or organ failure — such as terminal cancer — that would make it difficult to take part in the study
  • People currently experiencing significant problems with alcohol or substance misuse
  • People with a significant neurological or psychiatric illness (applies to Groups A and B only; confirm for other groups with trial site)
  • People who are unwilling to undergo a lumbar puncture (a procedure to collect fluid from around the spine), an MRI scan, or a PET scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Erik Stomrud, MD, Phd, Skåne University Hospital, and Lund University

Phone: +46 40 33 10 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Skane University Hospital
Registry
ClinicalTrials.gov
Start date
15 May 2017
Est. completion
1 December 2036

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Clinical diagnosis; Clinical Dementia Rating-Sum of Boxes (CDR-SB)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov